Nifedipine
- Generic Name
- Nifedipine
- Brand Names
- Adalat, Afeditab CR, Nifediac, Nifedical, Procardia
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18N2O6
- CAS Number
- 21829-25-4
- Unique Ingredient Identifier
- I9ZF7L6G2L
- Background
Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to nicardipine. Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972. Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is amlodipine.
Nifedipine was granted FDA approval on 31 December 1981.
- Indication
Nifedipine capsules are indicated to treat vasospastic angina and chronic stable angina. Extended release tablets are indicated to treat vasospastic angina, chronic stable angina, and hypertension.
- Associated Conditions
- Achalasia, Chronic Stable Angina Pectoris, Fissure;Anal, Hypertension, Hypertensive Emergency, Premature Labour, Proctalgia, Pulmonary Edemas, Pulmonary Hypertension (PH), Raynaud's Phenomenon, Ureteral Calculus, Vasospastic Angina
Nifedipine vs Placebo for Maintenance Tocolysis of Preterm Labor.
- Conditions
- Obstetric Labor, PrematureVenous Thrombosis
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2011-06-13
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 70
- Registration Number
- NCT00185952
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Magnesium Sulfate Versus Nifedipine for the Acute Tocolysis of Preterm Labor: A Prospective, Randomized Trial
- Conditions
- Obstetric Labor, Premature
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 192
- Registration Number
- NCT00185900
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
A Study of Nifecardia SRFC and Adalat OROS in the Treatment of Patients With Essential Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2005-12-21
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00173667
- Locations
- 🇨🇳
Cardiovascular Division, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Two Dose Regimens of Nifedipine for the Management of Preterm Labor
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2013-07-19
- Lead Sponsor
- American University of Beirut Medical Center
- Target Recruit Count
- 102
- Registration Number
- NCT00137501
- Locations
- 🇱🇧
American University of Beirut Medical Center, Beirut, Lebanon
Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets
- Conditions
- Congenital Adrenal Hyperplasia
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Registration Number
- NCT00000102
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Asymptomatic Cardiac Ischemia Pilot (ACIP) Study
- Conditions
- Cardiovascular DiseasesCoronary DiseaseMyocardial IschemiaHeart Diseases
Raynaud's Treatment Study (RTS)
- Conditions
- Raynaud's DiseaseVascular DiseasesCardiovascular DiseasesHeart Diseases
Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes
- Conditions
- Diabetic Nephropathy
- Interventions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2018-03-07
- Target Recruit Count
- 160
- Registration Number
- NCT00004266
- Locations
- 🇺🇸
Hennepin County Medical Center, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.